HC Wainwright set a $6.00 price target on Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report report published on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
Other research analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Aptose Biosciences from a sell rating to a hold rating in a research note on Monday, December 25th. ValuEngine lowered shares of Aptose Biosciences from a sell rating to a strong sell rating in a research note on Friday, December 1st. Finally, Canaccord Genuity set a $7.00 target price on shares of Aptose Biosciences and gave the company a buy rating in a research note on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $5.00.
Aptose Biosciences (NASDAQ APTO) opened at $3.28 on Wednesday. The stock has a market cap of $93.45, a PE ratio of -5.13 and a beta of 2.81. Aptose Biosciences has a one year low of $0.78 and a one year high of $3.90.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.